Immunocore Corp (IMCR) Long-Term Debt to Capital Ratio

Immunocore Holdings plc - graphic logo of issuer IMCR

Immunocore Holdings plc (IMCR) develops advanced T-cell receptor-based therapies to combat occult neoplasms. Business growth is driven by the global commercialization of Kimmtrak, the efficacy of new developments, and cost discipline, while the standalone long-term debt metric stands at 1.11. The price action of the company on the GURU.Markets platform demonstrates the correlation between financial metrics and the asset's market value.

Long-Term Debt to Equity: Immunocore Holdings plc (IMCR) for 07/04/2022 - 11/01/2026

Analytical breakdowns for Immunocore Holdings plc

- market price and analyst price targets:
Market Price Immunocore Holdings|IMCR - Price Target Chart
- market capitalization details:
Market Capitalization Immunocore Holdings|IMCR - Enterprise Value
- issuer book value statistics:
Accounting Value per Share Immunocore|IMCR - Company Book Value|Market-to-Book Ratio immunocore.com|IMCR - Aggregate Company Assets
- debt and solvency information:
Debt to Equity Immunocore Holdings plc|IMCR - Long-Term Debt to Equity|Current Liabilities to Capital immunocore.com|IMCR - Company Aggregate Debts|Debt to Net Assets Immunocore Holdings|IMCR - Company Long-Term Liabilities|Short-Term Debt Immunocore|Intermediate Coverage Ratio immunocore.com
- company profitability and valuation multiples indicators:
IMCR - Net Profit
Summary company analysis:IMCR - Immunocore Holdings
Brand item of Immunocore PLC

Immunocore Holdings plc (IMCR) is strengthening its market position by implementing energy-efficient ESG technologies into the production of immuno-oncology drugs to optimize costs. The long-term debt-to-equity ratio digitizes the resilience of this strategy by measuring the share of loans with maturities exceeding one year within the financing structure, which allows this long-term debt-to-equity chart to determine the balance between leverage and the business's financial autonomy.

Competing companies

Long-Term Liabilities to Capital ImmunityBio Inc IBRX|Long-Term Debt to Equity Janux Pharma (JANX)|Arcus Corp - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital ZYME (Zymeworks Inc.)|TNGX - Long-Term Debt to Equity Ratio|IOVA - Long-Term Debt to Equity|Long-Term Liabilities to Capital Immatics NV|Xencor Corp (XNCR) - Long-Term Debt to Equity|CMPX (Compass Therapeutics Corp) - Long-Term Debt to Equity|Long-Term Debt to Equity Replimune Group, Inc.|Long-Term Liabilities to Capital lyell.com LYEL|Long-Term Debt to Capital IPHA|pyxisoncology.com (PYXS) - Long-Term Indebtedness to Equity|Compugen - Long-Term Debt to Equity Ratio|IO Biotech Inc. (IOBT) - Long-Term Liabilities to Capital|STRO: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient INKT (minktherapeutics.com)|HOWL: Long-Term Debt to Capital|IMMX - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity ALX Oncology Holdings|Long-Term Debt to Equity Ratio cuebiopharma.com (CUE)|Long-Term Debt to Equity PDS Biotechnology (PDSB)|Long-Term Debt to Equity Ratio sonnetbio.com SONN|MAIA Biotechnology, Inc. - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Liminatus Pharma Inc. LIMN|LVTX - Long-Term Debt to Equity|NXTC (NextCure Corporation) - Long-Term Debt to Capital Ratio|leaptx.com (LPTX) - Long-Term Debt to Equity|Long-Term Liabilities to Capital Intensity Therapeutics, Inc. (INTS)|Long-Term Debt to Equity Ratio SNSE|TOVX - Long-Term Indebtedness to Equity|Long-Term Debt to Equity Ratio GRTS (Gritstone bio, Inc.)|Long-Term Loans to Capital Ratio KA|Long-Term Debt to Capital NEXI (NexImmune, Inc.)|Long-Term Debt to Capital Coefficient TSBX|Vaccinex - Long-Term Debt to Capital|Long-Term Liabilities to Capital Harpoon Therapeutics Inc